Cardiology News, Research Articles | Heart Disease, Disorder Studies
Rethinking Beta-Blocker Use Following Acute Myocardial Infarction. By Tori Rodriguez, MA, LPC, AHC. A discussion of the use of beta-blocker therapy following AMI, with Christopher Granger, MD, Gregg Fonarow, MD, and Carlin S Long, MD.
Semaglutide Lowers Heart Failure Risks in Patients With Type 2 …
2 days ago · A prespecified analysis of the FLOW trial demonstrates the benefit of semaglutide in reducing the composite risk of heart failure events and cardiovascular death in patients with type 2 diabetes and CKD. Semaglutide reduces risks heart failure (HF) and cardiovascular death in a high-risk population ...
PCI vs CABG - The Cardiology Advisor
Dec 5, 2022 · Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are two options for the treatment and management of coronary artery disease. Advancements in imaging techniques, including computed tomography, magnetic resonance imaging, intravascular ultrasound, and optical coherence tomography, have improved the detection of patients’ needs for PCI vs CABG interventions.
COVID-19 Hospitalization Equivalent to Coronary Artery Disease …
3 days ago · HealthDay News — Hospitalization for COVID-19 represents a coronary artery disease risk equivalent, contributing to an increased risk for major adverse cardiovascular events (MACE), according to a study published online Oct. 9 in Arteriosclerosis, Thrombosis, and Vascular Biology.. James R. Hilser, from the Keck School of Medicine at the University of Southern California in Los Angeles, and ...
Catheter Ablation Reduces Atrial Fibrillation Symptoms Across HF ...
Oct 9, 2024 · Significant reductions in atrial fibrillation (AF) symptoms, AF-related hospitalization, and heart failure (HF) symptoms were found following catheter ablation (CA) across HF subtypes, according to study findings published in Circulation: Arrhythmia and Electrophysiology. Investigators characterized the impact of CA on AF occurrence, AF-related ...
Heart Failure: A 2022 ACC/AHA/HFSA Guideline for Patient …
Nov 10, 2022 · A new guideline offers updated recommendations for the assessment and management of heart failure (HF).The guideline, issued by the American College of Cardiology (ACC), the American Heart Association (AHA), and the Heart Failure Society of America (HFSA), combines and replaces the 2013 American College of Cardiology Foundation (ACCF)/AHA guideline for HF management and the 2017 focused update ...
Atrial Fibrillation Recurrence Risk After Ablation Is Greater in …
Oct 2, 2024 · Women vs men have a higher atrial fibrillation (AF) recurrence risk within 3 years of index radiofrequency ablation, according to study results submitted to the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024, held virtually from September 27 to 30, 2024.
Apolipoprotein B/A1 Ratio Predicts Cardiovascular Complications …
Oct 11, 2024 · Apolipoprotein B/A1 Ratio Predicts Cardiovascular Complications in T2D. Higher ApoB/ApoA1 ratio was linked to cardiovascular complications but did not improve predictive value of current models. Higher apolipoprotein B to A1 (ApoB/ApoA1) ratio is linked to both major macrovascular and microvascular events among individuals with type 2 diabetes ...
The AHA’s PREVENT Equations Recommend Fewer Adults Should …
Jul 10, 2024 · The Predicting Risk of Cardiovascular Disease Events (PREVENT) equations from the American Heart Association (AHA) recommend that fewer adults use statin therapy. These findings were published in JAMA Internal Medicine. In 2023, the AHA published the PREVENT equations for estimating 10-year atherosclerotic cardiovascular disease (ASCVD) risk.
Lower-Dose Anticoagulants May Be Effective in Older Patients …
Aug 12, 2024 · Among patients aged 80 years and older with atrial fibrillation (AF), major bleeding events are reduced with edoxaban 30 mg compared with edoxaban 60 mg or warfarin, without an increase in ischemic events, according to a study in JAMA Cardiology.. The results are from a post hoc analysis of the ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation ...